EN | RU
EN | RU

Help Support

Back

Study reveals long-term efficacy and safety of upadacitinib and TCS in atopic dermatitis

Study reveals long-term efficacy and safety of upadacitinib and TCS in atopic dermatitis Study reveals long-term efficacy and safety of upadacitinib and TCS in atopic dermatitis
Study reveals long-term efficacy and safety of upadacitinib and TCS in atopic dermatitis Study reveals long-term efficacy and safety of upadacitinib and TCS in atopic dermatitis

What's new?

Upadacitinib + topical corticosteroids offer long-term efficacy and favorable safety in patients having moderate-to-severe atopic dermatitis.

The Phase 3 AD Up study findings through 52 weeks favored the potential of upadacitinib plus topical corticosteroids (TCS) as an effective, safe and well-tolerated long-term therapeutic choice with a positive benefit-risk profile in atopic dermatitis. This study aimed to determine the efficacy and safety of upadacitinib+TCS through 52 weeks in adults and adolescents (12-75 years) suffering from chronic atopic dermatitis.

Participants were randomly allocated to once-daily 15mg upadacitinib+TCS, 30mg upadacitinib+TCS, or placebo+TCS (re-randomized at week 16 to upadacitinib+TCS). Evaluation of the proportion of people attaining ≥75% improvement in Eczema Area and Severity Index (EASI-75), Worst Pruritis Numerical Rating Scale (WP-NRS) improvement ≥4, and validated Investigator’s Global Assessment for atopic dermatitis of clear or almost clear with ≥ 2 grades of improvement (vIGA-atopic dermatitis 0/1) was done through week 52.

Out of 901 patients, 300 were randomized to 15 mg upadacitinib+TCS, 297 to 30mg upadacitinib + TCS, and 304 to placebo + TCS. The efficacy of upadacitinib plus TCS at week 16 was found to be maintained through week 52 for all the outcomes. At week 52, the percentage of people attaining  EASI-75,  vIGA-atopic dermatitis 0/1, and  WP-NRS improvement ≥4 is shown in Table 1:


The combination of upadacitinib and TCS showed good tolerability over 52 weeks. No novel safety risks beyond the current label were noted. No deaths were noted; major adverse cardiovascular events and venous thromboembolic events were not frequent (≤0.2/100 patient-years). Thus, the findings depicted favorable safety and long-term maintenance of efficacy of upadacitinib plus TCS for the management of atopic dermatitis.

Source:

The Journal of Allergy and Clinical Immunology

Article:

Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results

Authors:

Jonathan I Silverberg et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: